Serotonin in antipsychotic drugs action

Behavioural Brain Research

Volumn 277, Issue , 2015, Pages 125-135

  Amato, Davide ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

5 HT; 5 HT levels; Affinity; Agonism; Antagonism; Antipsychotic drugs; Inverse agonism; Microdialysis; Partial agonism; Receptors

Indexed keywords

ARIPIPRAZOLE; BLONANSERIN; CHLORPROMAZINE; CLOZAPINE; EMONAPRIDE; HALOPERIDOL; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; TANDOSPIRONE; ZIPRASIDONE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; DOPAMINE; SEROTONIN RECEPTOR;

BINDING AFFINITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SCHIZOPHRENIA; SEROTONIN BRAIN LEVEL; SEROTONIN RELEASE; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; ANIMAL; METABOLISM;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE; HUMANS; NEUROTRANSMITTER AGENTS; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN;

EID: 84912122805     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.07.025     Document Type: Review

References (173)

1. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223. http://dx.doi.org/10.1056/NEJMoa051688.
2. Buchanan R.W., Gold J.M. Negative symptoms: diagnosis, treatment and prognosis. Int Clin Psychopharmacol 1996, 11(Suppl 2):3-11.
3. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 1996, 153:321-330.
4. Greenwood K.E., Landau S., Wykes T. Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. Schizophr Bull 2005, 31:910-921. http://dx.doi.org/10.1093/schbul/sbi035.
5. Marder S.R., Roth B., Sullivan P.F., Scolnick E.M., Nestler E.J., Geyer M.A., et al. Advancing drug discovery for schizophrenia. Ann N Y Acad Sci 2011, 1236:30-43. http://dx.doi.org/10.1111/j. 1749-6632.2011.06216.x.
6. Meltzer H.Y., Matsubara S., Lee J.C. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989, 25:390-392.
7. Seeman P. Targeting the dopamine d2 receptor in schizophrenia. Expert Opin Ther Targets 2006, 10:515-531. http://dx.doi.org/10.1517/14728222.10.4.515.
8. Seeman P., Chau-Wong M., Tedesco J., Wong K. Dopamine receptors in human and calf brains, using [3h]apomorphine and an antipsychotic drug. Proc Natl Acad Sci U S A 1976, 73:4354-4358.
9. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192:481-483.
10. Kapur S., Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:1081-1090. http://dx.doi.org/10.1016/j.pnpbp.2003.09.004.
11. Abbott A. Schizophrenia the drug deadlock. Nature 2010, 468:158-159. http://dx.doi.org/10.1038/468158a.
12. Seeman P. Atypical antipsychotics mechanism of action. Can J Psychiatry 2002, 47:27-38.
13. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992, 49:538-544.
14. Kapur S., Zipursky R.B., Remington G. Clinical and theoretical implications of 5-Ht2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999, 156:286-293.
15. Dahlstroem A., Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand Suppl 1964, (SUPPL 232):1-55.
16. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., et al. International union of pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994, 46:157-203.
17. Barnes N.M., Sharp T. A review of central 5-Ht receptors and their function. Neuropharmacology 1999, 38:1083-1152.
18. Jacobs B.L., Azmitia E.C. Structure and function of the brain serotonin system. Physiol Rev 1992, 72:165-229.
19. Fuxe K. Evidence for the existence of monoamine neurons in the central nervous system 3. The monoamine nerve terminal. Z Zellforsch Mikrosk Anat 1965, 65:573-596.
20. Nicoll R.A., Malenka R.C., Kauer J.A. Functional comparison of neurotransmitter receptor subtypes in mammalian central nervous system. Physiol Rev 1990, 70:513-565.
21. Marek G.J., Aghajanian G.K. Protein kinase C inhibitors enhance the 5-Ht2a receptor-mediated excitatory effects of serotonin on interneurons in rat piriform cortex. Synapse 1995, 21:123-130. http://dx.doi.org/10.1002/syn.890210205.
22. Andrade R., Nicoll R.A. Pharmacologically distinct actions of serotonin on single pyramidal neurones of the rat hippocampus recorded in vitro. J Physiol 1987, 394:99-124.
23. Andrade R., Nicoll R.A. Novel anxiolytics discriminate between postsynaptic serotonin receptors mediating different physiological responses on single neurons of the rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 1987, 336:5-10.
24. Van den Hooff P., Galvan M. Electrophysiology of the 5-Ht1a ligand Mdl 73005ef in the rat hippocampal slice. Eur J Pharmacol 1991, 196:291-298.
25. Corradetti R., Pugliese A.M., Le Poul E., Laaris N., Hamon M., Lanfumey L. Electrophysiological effects of way 100635, a New 5-Ht1a receptor antagonist, on dorsal raphe nucleus serotoninergic neurones and ca1 pyramidal cells in vitro. Acta Physiol Hung 1996, 84:407-409.
26. Craven R., Grahame-Smith D., Newberry N. Way-100635 and Gr127935, effects on 5-hydroxytryptamine-containing neurones. Eur J Pharmacol 1994, 271:R1-R3.
27. Hajos M., Gartside S.E., Villa A.E., Sharp T. Evidence for a repetitive (burst) firing pattern in a sub-population of 5-hydroxytryptamine neurons in the dorsal and median raphe nuclei of the rat. Neuroscience 1995, 69:189-197.
28. Hajos M., Gartside S.E., Sharp T. Inhibition of median and dorsal raphe neurones following administration of the selective serotonin reuptake inhibitor paroxetine. Naunyn Schmiedebergs Arch Pharmacol 1995, 351:624-629.
29. Gartside S.E., Umbers V., Hajos M., Sharp T. Interaction between a selective 5-Ht1a receptor antagonist and an ssri in vivo: effects on 5-Ht cell firing and extracellular 5-Ht. Br J Pharmacol 1995, 115:1064-1070.
30. Gartside S.E., Umbers V., Sharp T. Inhibition of 5-Ht cell firing in the Drn by non-selective 5-Ht reuptake inhibitors: studies on the role of 5-Ht1a autoreceptors and noradrenergic mechanisms. Psychopharmacology (Berl) 1997, 130:261-268.
31. Sinton C.M., Fallon S.L. Electrophysiological evidence for a functional differentiation between subtypes of the 5-Ht1 receptor. Eur J Pharmacol 1988, 157:173-181.
32. Blier P., Serrano A., Scatton B. Differential responsiveness of the rat dorsal and median raphe 5-Ht systems to 5-Ht1 receptor agonists and P-chloroamphetamine. Synapse 1990, 5:120-133. http://dx.doi.org/10.1002/syn.890050206.
33. Casanovas J.M., Artigas F. Differential effects of ipsapirone on 5-hydroxytryptamine release in the dorsal and median raphe neuronal pathways. J Neurochem 1996, 67:1945-1952.
34. Gartside S.E., McQuade R., Sharp T. Effects of repeated administration of 3,4-methylenedioxymethamphetamine on 5-hydroxytryptamine neuronal activity and release in the rat brain in vivo. J Pharmacol Exp Ther 1996, 279:277-283.
35. Ceci A., Baschirotto A., Borsini F. The inhibitory effect of 8-Oh-Dpat on the firing activity of dorsal raphe serotoninergic neurons in rats is attenuated by lesion of the frontal cortex. Neuropharmacology 1994, 33:709-713.
36. Jolas T., Schreiber R., Laporte A.M., Chastanet M., De Vry J., Glaser T., et al. Are postsynaptic 5-Ht1a receptors involved in the anxiolytic effects of 5-Ht1a receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat?. J Pharmacol Exp Ther 1995, 272:920-929.
37. Hajos M., Hajos-Korcsok E., Sharp T. Role of the medial prefrontal cortex in 5-Ht1a receptor-induced inhibition of 5-Ht neuronal activity in the rat. Br J Pharmacol 1999, 126:1741-1750. http://dx.doi.org/10.1038/sj.bjp.0702510.
38. Leysen J.E., Niemegeers C.J., Tollenaere J.P., Laduron P.M. Serotonergic component of neuroleptic receptors. Nature 1978, 272:168-171.
39. Peroutka S.J., Snyder S.H. Multiple serotonin receptors: differential binding of [3h]5-hydroxytryptamine, [3h]lysergic acid diethylamide and [3h]Spiroperidol. Mol Pharmacol 1979, 16:687-699.
40. Pazos A., Cortes R., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain, Ii. serotonin-2 receptors. Brain Res 1985, 346:231-249.
41. Pazos A., Probst A., Palacios J.M. Serotonin receptors in the human brain--Iv, autoradiographic mapping of serotonin-2 receptors. Neuroscience 1987, 21:123-139.
42. Lopez-Gimenez J.F., Mengod G., Palacios J.M., Vilaro M.T. Selective visualization of rat brain 5-Ht2a receptors by autoradiography with [3h]Mdl 100,907. Naunyn Schmiedebergs Arch Pharmacol 1997, 356:446-454.
43. Morilak D.A., Garlow S.J., Ciaranello R.D. Immunocytochemical localization and description of neurons expressing serotonin2 receptors in the rat brain. Neuroscience 1993, 54:701-717.
44. Morilak D.A., Somogyi P., Lujan-Miras R., Ciaranello R.D. Neurons expressing 5-Ht2 receptors in the rat brain: neurochemical identification of cell types by immunocytochemistry. Neuropsychopharmacology 1994, 11:157-166. http://dx.doi.org/10.1038/sj.npp.1380102.
45. Pompeiano M., Palacios J.M., Mengod G. Distribution of the serotonin 5-Ht2 receptor family mrnas: comparison between 5-Ht2a and 5-Ht2c receptors. Brain Res Mol Brain Res 1994, 23:163-178.
46. Burnet P.W., Eastwood S.L., Lacey K., Harrison P.J. The distribution of 5-Ht1a and 5-Ht2a receptor Mrna in human brain. Brain Res 1995, 676:157-168.
47. Deecher D.C., Wilcox B.D., Dave V., Rossman P.A., Kimelberg H.K. Detection of 5-hydroxytryptamine2 receptors by radioligand binding, northern blot analysis, and Ca2+ responses in rat primary astrocyte cultures. J Neurosci Res 1993, 35:246-256. http://dx.doi.org/10.1002/jnr.490350304.
48. Francis P.T., Pangalos M.N., Pearson R.C., Middlemiss D.N., Stratmann G.C., Bowen D.M. 5-Hydroxytryptamine1a but not 5-hydroxytryptamine2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin. J Pharmacol Exp Ther 1992, 261:1273-1281.
49. Wright D.E., Seroogy K.B., Lundgren K.H., Davis B.M., Jennes L. Comparative localization of serotonin1a, 1c, and 2 receptor subtype Mrnas in rat brain. J Comp Neurol 1995, 351:357-373. http://dx.doi.org/10.1002/cne.903510304.
50. Morilak D.A., Ciaranello R.D. 5-Ht2 receptor immunoreactivity on cholinergic neurons of the pontomesencephalic tegmentum shown by double immunofluorescence. Brain Res 1993, 627:49-54.
51. Blue M.E., Yagaloff K.A., Mamounas L.A., Hartig P.R., Molliver M.E. Correspondence between 5-Ht2 receptors and serotonergic axons in rat neocortex. Brain Res 1988, 453:315-328.
52. Godbout R., Mantz J., Glowinski J., Thierry A.M. The novel 5-Ht2 receptor antagonist, Rp 62203, selectively blocks serotoninergic but not dopaminergic-induced inhibition in the rat prefrontal cortex. Eur J Pharmacol 1991, 204:97-100.
53. Boess F.G., Martin I.L. Molecular biology of 5-Ht receptors. Neuropharmacology 1994, 33:275-317.
54. Wolf W.A., Schutz L.J. The serotonin 5-Ht2c receptor is a prominent serotonin receptor in basal ganglia: evidence from functional studies on serotonin-mediated phosphoinositide hydrolysis. J Neurochem 1997, 69:1449-1458.
55. Sanders-Bush E. Adaptive regulation of central serotonin receptors linked to phosphoinositide hydrolysis. Neuropsychopharmacology 1990, 3:411-416.
56. Briddon S.J., Leslie R.A., Elliott J.M. Comparative desensitization of the human 5-Ht2a and 5-Ht2c receptors expressed in the human neuroblastoma cell line Sh-Sy5y. Br J Pharmacol 1998, 125:727-734. http://dx.doi.org/10.1038/sj.bjp.0702145.
57. Roth B.L., Ciaranello R.D. Chronic mianserin treatment decreases 5-Ht2 receptor binding without altering 5-Ht2 receptor Mrna levels. Eur J Pharmacol 1991, 207:169-172.
58. Egan C., Herrick-Davis K., Teitler M. Creation of a constitutively activated state of the 5-Ht2a receptor by site-directed mutagenesis: revelation of inverse agonist activity of antagonists. Ann N Y Acad Sci 1998, 861:136-139.
59. Strange P.G. Antipsychotic drug action: antagonism, inverse agonism or partial agonism. Trends Pharmacol Sci 2008, 29:314-321. http://dx.doi.org/10.1016/j.tips.2008.03.009.
60. North R.A., Uchimura N. 5-Hydroxytryptamine acts at 5-Ht2 receptors to decrease potassium conductance in rat nucleus accumbens neurones. J Physiol 1989, 417:1-12.
61. Araneda R., Andrade R. 5-Hydroxytryptamine2 and 5-hydroxytryptamine 1a receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 1991, 40:399-412.
62. Piguet P., Galvan M. Transient and long-lasting actions of 5-Ht on rat dentate gyrus neurones in vitro. J Physiol 1994, 481(Pt 3):629-639.
63. Aghajanian G.K., Lakoski J.M. Hyperpolarization of serotonergic neurons by serotonin and Lsd: studies in brain slices showing increased K+ conductance. Brain Res 1984, 305:181-185.
64. Sheldon P.W., Aghajanian G.K. Excitatory responses to serotonin (5-Ht) in neurons of the rat piriform cortex: evidence for mediation by 5-Ht1c receptors in pyramidal cells and 5-Ht2 receptors in interneurons. Synapse 1991, 9:208-218. http://dx.doi.org/10.1002/syn.890090307.
65. Marek G.J., Aghajanian G.K. Excitation of interneurons in piriform cortex by 5-hydroxytryptamine: blockade by Mdl 100,907, a highly selective 5-Ht2a receptor antagonist. Eur J Pharmacol 1994, 259:137-141.
66. Gorea E., Davenne D., Lanfumey L., Chastanet M., Adrien J. Regulation of noradrenergic coerulean neuronal firing mediated by 5-Ht2 receptors: involvement of the prepositus hypoglossal nucleus. Neuropharmacology 1991, 30:1309-1318.
67. Radja F., Laporte A.M., Daval G., Verge D., Gozlan H., Hamon M. Autoradiography of serotonin receptor subtypes in the central nervous system. Neurochem Int 1991, 18:1-15.
68. Rick C.E., Stanford I.M., Lacey M.G. Excitation of rat substantia nigra pars reticulata neurons by 5-hydroxytryptamine in vitro: evidence for a direct action mediated by 5-hydroxytryptamine2c receptors. Neuroscience 1995, 69:903-913.
69. Baxter G., Kennett G., Blaney F., Blackburn T. 5-Ht2 receptor subtypes: a family re-united?. Trends Pharmacol Sci 1995, 16:105-110.
70. Bonhaus D.W., Weinhardt K.K., Taylor M., DeSouza A., McNeeley P.M., Szczepanski K., et al. Rs-102221: a novel high affinity and selective, 5-Ht2c receptor antagonist. Neuropharmacology 1997, 36:621-629.
71. Kennett G.A., Wood M.D., Bright F., Trail B., Riley G., Holland V., et al. Sb 242084, a selective and brain penetrant 5-Ht2c receptor antagonist. Neuropharmacology 1997, 36:609-620.
72. Sanders-Bush E., Burris K.D., Knoth K. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J Pharmacol Exp Ther 1988, 246:924-928.
73. Julius D., MacDermott A.B., Axel R., Jessell T.M. Molecular characterization of a functional Cdna encoding the serotonin 1c receptor. Science 1988, 241:558-564.
74. Barker E.L., Westphal R.S., Schmidt D., Sanders-Bush E. Constitutively active 5-hydroxytryptamine2c receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem 1994, 269:11687-11690.
75. Shaw E., Woolley D.W. Some serotoninlike activities of lysergic acid diethylamide. Science 1956, 124:121-122.
76. Randrup A., Munkvad I. Special antagonism of amphetamine-induced abnormal behaviour, inhibition of stereotyped activity with increase of some normal activities. Psychopharmacologia 1965, 7:416-422.
77. Carlsson A. Antipsychotic drugs and catecholamine synapses. J Psychiatr Res 1974, 11:57-64.
78. Snyder S.H. Stereoselective features of catecholamine dispostion and their behavioral implications. J Psychiatr Res 1974, 11:31-39.
79. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976, 261:717-719.
80. Bennett J.P., Enna S.J., Bylund D.B., Gillin J.C., Wyatt R.J., Snyder S.H. Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 1979, 36:927-934.
81. Rasmussen H., Erritzoe D., Andersen R., Ebdrup B.H., Aggernaes B., Oranje B., et al. Decreased frontal serotonin2a receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Arch Gen Psychiatry 2010, 67:9-16. http://dx.doi.org/10.1001/archgenpsychiatry.2009.176.
82. Roth B.L., Hanizavareh S.M., Blum A.E. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl) 2004, 174:17-24. http://dx.doi.org/10.1007/s00213-003-1683-8.
83. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996, 153:466-476.
84. Kuroki T., Nagao N., Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res 2008, 172:199-212. http://dx.doi.org/10.1016/S0079-6123(08)00910-2.
85. Egerton A., Ahmad R., Hirani E., Grasby P.M. Modulation of striatal dopamine release by 5-Ht2a and 5-Ht2c receptor antagonists: [11c]Raclopride pet studies in the rat. Psychopharmacology (Berl) 2008, 200:487-496. http://dx.doi.org/10.1007/s00213-008-1226-4.
86. Di Pietro N.C., Seamans J.K. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action. Pharmacopsychiatry 2007, 40(Suppl 1):S27-S33. http://dx.doi.org/10.1055/s-2007-992133.
87. Hertel P., Fagerquist M.V., Svensson T.H. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by Alpha2 adrenoceptor blockade. Science 1999, 286:105-107.
88. Antoniou K., Bekris S., Saranti M., Stathis P., Rimikis M., Papadopoulou-Daifoti Z. The effects of antipsychotic drugs on serotonergic activity in the rat hippocampus. Eur Neuropsychopharmacol 2000, 10:315-324.
89. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996, 124:57-73.
90. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999, 21:106S-150S. http://dx.doi.org/10.1016/S0893-133X(99)00046-9.
91. Zocchi A., Fabbri D., Heidbreder C.A. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci Lett 2005, 387:157-161. http://dx.doi.org/10.1016/j.neulet.2005.06.035.
92. Bortolozzi A., Diaz-Mataix L., Toth M., Celada P., Artigas F. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl) 2007, 191:745-758. http://dx.doi.org/10.1007/s00213-007-0698-y.
93. Carli M., Calcagno E., Mainolfi P., Mainini E., Invernizzi R.W. Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex. Psychopharmacology (Berl) 2011, 214:639-652. http://dx.doi.org/10.1007/s00213-010-2065-7.
94. Amato D., Natesan S., Yavich L., Kapur S., Muller C.P. Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment. Int J Neuropsychopharmacol 2011, 14:1327-1339. http://dx.doi.org/10.1017/S1461145711000010.
95. Amargos-Bosch M., Artigas F., Adell A. Effects of acute olanzapine after sustained fluoxetine on extracellular monoamine levels in the rat medial prefrontal cortex. Eur J Pharmacol 2005, 516:235-238. http://dx.doi.org/10.1016/j.ejphar.2005.05.004.
96. Amargos-Bosch M., Adell A., Bortolozzi A., Artigas F. Stimulation of alpha1-adrenoceptors in the rat medial prefrontal cortex increases the local in vivo 5-hydroxytryptamine release: reversal by antipsychotic drugs. J Neurochem 2003, 87:831-842.
97. Amargos-Bosch M., Adell A., Artigas F. Antipsychotic drugs reverse the ampa receptor-stimulated release of 5-Ht in the medial prefrontal cortex. J Neurochem 2007, 102:550-561. http://dx.doi.org/10.1111/j. 1471-4159.2007.04532.x.
98. Assie M.B., Cosi C., Koek W. 5-Ht1a receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine. Eur J Pharmacol 1997, 334:141-147.
99. Assie M.B., Ravailhe V., Faucillon V., Newman-Tancredi A. Contrasting contribution of 5-hydroxytryptamine 1a receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 2005, 315:265-272. http://dx.doi.org/10.1124/jpet.105.087163.
100. Huang M, Panos JJ, Kwon S, Oyamada Y, Rajagopal L, Meltzer HY. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-Ht) and Da D antagonism and 5-Ht partial agonism. J Neurochem 2013, doi:10.1111/jnc.12512.
101. Ohoyama K., Yamamura S., Hamaguchi T., Nakagawa M., Motomura E., Shiroyama T., et al. Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex. Eur J Pharmacol 2011, 653:47-57. http://dx.doi.org/10.1016/j.ejphar.2010.11.023.
102. Denys D., Klompmakers A.A., Westenberg H.G. Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology (Berl) 2004, 176:195-203. http://dx.doi.org/10.1007/s00213-004-1880-0.
103. Koch S., Perry K.W., Bymaster F.P. Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology 2004, 46:232-242.
104. Zhang W., Perry K.W., Wong D.T., Potts B.D., Bao J., Tollefson G.D., et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000, 23:250-262. http://dx.doi.org/10.1016/S0893-133X(00)00119-6.
105. Amargos-Bosch M., Lopez-Gil X., Artigas F., Adell A. Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine. Int J Neuropsychopharmacol 2006, 9:565-573. http://dx.doi.org/10.1017/S1461145705005900.
106. Ferre S., Artigas F. Clozapine decreases serotonin extracellular levels in the nucleus accumbens by a dopamine receptor-independent mechanism. Neurosci Lett 1995, 187:61-64.
107. Lopez-Gil X., Babot Z., Amargos-Bosch M., Sunol C., Artigas F., Adell A. Clozapine and haloperidol differently suppress the Mk-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 2007, 32:2087-2097. http://dx.doi.org/10.1038/sj.npp.1301356.
108. Hertel P., Nomikos G.G., Schilstrom B., Arborelius L., Svensson T.H. Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: role of alpha 2-adrenoceptor antagonism. Neuropsychopharmacology 1997, 17:44-55. http://dx.doi.org/10.1016/S0893-133X(97)00002-X.
109. Kroeze W.K., Hufeisen S.J., Popadak B.A., Renock S.M., Steinberg S., Ernsberger P., et al. H1-Histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003, 28:519-526. http://dx.doi.org/10.1038/sj.npp.1300027.
110. Newman-Tancredi A., Rivet J., Chaput C., Touzard M., Verriele L., Millan M.J. The 5ht(1a) receptor ligand, S15535, antagonises G-protein activation: a [35s]Gtpgammas and [3h]S15535 autoradiography study. Eur J Pharmacol 1999, 384:111-121.
111. Weiner D.M., Burstein E.S., Nash N., Croston G.E., Currier E.A., Vanover K.E., et al. 5-Hydroxytryptamine2a receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 2001, 299:268-276.
112. Newman-Tancredi A., Assie M.B., Leduc N., Ormiere A.M., Danty N., Cosi C. Novel antipsychotics activate recombinant human and native rat serotonin 5-Ht1a receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 2005, 8:341-356. http://dx.doi.org/10.1017/S1461145704005000.
113. Jensen N.H., Rodriguiz R.M., Caron M.G., Wetsel W.C., Rothman R.B., Roth B.L. N-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-Ht1a agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008, 33:2303-2312. http://dx.doi.org/10.1038/sj.npp.1301646.
114. Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics?. A review of the evidence. Neuropsychopharmacology 1998, 18:63-101. http://dx.doi.org/10.1016/S0893-133X(97)00112-7.
115. Davies M.A., Sheffler D.J., Roth B.L. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 2004, 10:317-336.
116. Dahan L., Husum H., Mnie-Filali O., Arnt J., Hertel P., Haddjeri N. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. J Psychopharmacol 2009, 23:177-189. http://dx.doi.org/10.1177/0269881108089586.
117. Hamik A., Oksenberg D., Fischette C., Peroutka S.J. Analysis of tandospirone (Sm-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry 1990, 28:99-109.
118. Tanaka H., Tatsuno T., Shimizu H., Hirose A., Kumasaka Y., Nakamura M. Effects of tandospirone on second messenger systems and neurotransmitter release in the rat brain. Gen Pharmacol 1995, 26:1765-1772.
119. Ishibashi T., Horisawa T., Tokuda K., Ishiyama T., Ogasa M., Tagashira R., et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-Ht7) and 5-Ht1a receptor activity. J Pharmacol Exp Ther 2010, 334:171-181. http://dx.doi.org/10.1124/jpet.110.167346.
120. Newman-Tancredi A., Gavaudan S., Conte C., Chaput C., Touzard M., Verriele L., et al. Agonist and antagonist actions of antipsychotic agents at 5-Ht1a receptors: a [35s]Gtpgammas binding study. Eur J Pharmacol 1998, 355:245-256.
121. Cosi C., Koek W. Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-Ht(1a) receptors expressed in hela cells. Eur J Pharmacol 2001, 433:55-62.
122. Kuoppamaki M., Palvimaki E.P., Hietala J., Syvalahti E. Differential regulation of rat 5-Ht2a and 5-Ht2c receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs. Neuropsychopharmacology 1995, 13:139-150. http://dx.doi.org/10.1016/0893-133X(95)00049-J.
123. Deutch A.Y., Moghaddam B., Innis R.B., Krystal J.H., Aghajanian G.K., Bunney B.S., et al. Mechanisms of action of atypical antipsychotic drugs, implications for novel therapeutic strategies for schizophrenia. Schizophr Res 1991, 4:121-156.
124. Egan C.T., Herrick-Davis K., Teitler M. Creation of a constitutively activated state of the 5-hydroxytryptamine2a receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs. J Pharmacol Exp Ther 1998, 286:85-90.
125. Meltzer H.Y., Nash J.F. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 1991, 43:587-604.
126. Zhang W., Bymaster F.P. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5ht2a and muscarinic receptors. Psychopharmacology (Berl) 1999, 141:267-278.
127. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:1159-1172. http://dx.doi.org/10.1016/j.pnpbp.2003.09.010.
128. Leysen J.E., Janssen P.M., Schotte A., Luyten W.H., Megens A.A. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5ht2 receptors. Psychopharmacology (Berl) 1993, 112:S40-S54.
129. Richelson E., Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000, 68:29-39.
130. Tenjin T., Miyamoto S., Ninomiya Y., Kitajima R., Ogino S., Miyake N., et al. Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr Dis Treat 2013, 9:587-594. http://dx.doi.org/10.2147/NDT.S34433.
131. Herrick-Davis K., Grinde E., Teitler M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2c receptors. J Pharmacol Exp Ther 2000, 295:226-232.
132. Rauser L., Savage J.E., Meltzer H.Y., Roth B.L. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2c) receptor. J Pharmacol Exp Ther 2001, 299:83-89.
133. Ishiyama T., Tokuda K., Ishibashi T., Ito A., Toma S., Ohno Y. Lurasidone (Sm-13496), a novel atypical antipsychotic drug, reverses Mk-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 2007, 572:160-170. http://dx.doi.org/10.1016/j.ejphar.2007.06.058.
134. Suzuki H., Gen K., Inoue Y. Comparison of the anti-dopamine D(2) and anti-serotonin 5-Ht(2a) activities of chlorpromazine, bromperidol, haloperidol and second-generation antipsychotics parent compounds and metabolites thereof. J Psychopharmacol 2013, 27:396-400. http://dx.doi.org/10.1177/0269881113478281.
135. Hertel P., Nomikos G.G., Svensson T.H. Risperidone inhibits 5-hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5-hydroxytryptamine. Br J Pharmacol 1997, 122:1639-1646. http://dx.doi.org/10.1038/sj.bjp.0701561.
136. Tarazi F.I., Zhang K., Baldessarini R.J. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1a, 2a and 2c receptors in rat forebrain regions. Psychopharmacology (Berl) 2002, 161:263-270. http://dx.doi.org/10.1007/s00213-002-1016-3.
137. Santana N., Bortolozzi A., Serrats J., Mengod G., Artigas F. Expression of serotonin1a and serotonin2a receptors in pyramidal and gabaergic neurons of the rat prefrontal cortex. Cereb Cortex 2004, 14:1100-1109. http://dx.doi.org/10.1093/cercor/bhh070.
138. Fay R., Kubin L. 5-Ht(2a) Receptor-like protein is present in small neurons located in rat mesopontine cholinergic nuclei, but absent from cholinergic neurons. Neurosci Lett 2001, 314:77-81.
139. Ueno S., Bracamontes J., Zorumski C., Weiss D.S., Steinbach J.H. Bicuculline and gabazine are allosteric inhibitors of channel opening of the gabaa receptor. J Neurosci 1997, 17:625-634.
140. Iyer R.N., Bradberry C.W. Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J Pharmacol Exp Ther 1996, 277:40-47.
141. Williams G.V., Rao S.G., Goldman-Rakic P.S. The physiological role of 5-Ht2a receptors in working memory. J Neurosci 2002, 22:2843-2854. http://dx.doi.org/20026203.
142. Tyson P.J., Roberts K.H., Mortimer A.M. Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5ht-2a receptors?. Int J Neurosci 2004, 114:593-611. http://dx.doi.org/10.1080/00207450490430552.
143. Castelao J.F., Ferreira L., Gelders Y.G., Heylen S.L. The efficacy of the D2 and 5-Ht2 antagonist risperidone (R 64,766) in the treatment of chronic psychosis, an open dose-finding study. Schizophr Res 1989, 2:411-415.
144. Goff D.C., Evins A.E. Negative symptoms in schizophrenia: neurobiological models and treatment response. Harv Rev Psychiatry 1998, 6:59-77.
145. Silver H., Nassar A., Aharon N., Kaplan A. The onset and time course of response of negative symptoms to add-on fluvoxamine treatment. Int Clin Psychopharmacol 2003, 18:87-92. http://dx.doi.org/10.1097/01.yic.0000053666.88477.9d.
146. Silver H., Shmugliakov N. Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J Clin Psychopharmacol 1998, 18:208-211.
147. Silver H. Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 2001, 7:283-304.
148. Lane H.Y., Liu C.C., Chang W.H. Risperidone for exclusively negative symptoms. Am J Psychiatry 1999, 156:335.
149. Curtis V.A., Katsafouros K., Moller H.J., Medori R., Sacchetti E. Long-acting risperidone improves negative symptoms in stable psychotic patients. J Psychopharmacol 2008, 22:254-261. http://dx.doi.org/10.1177/0269881107082119.
150. Stroup T.S., Lieberman J.A., McEvoy J.P., Swartz M.S., Davis S.M., Rosenheck R.A., et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006, 163:611-622. http://dx.doi.org/10.1176/appi.ajp.163.4.611.
151. Maher A.R., Maglione M., Bagley S., Suttorp M., Hu J.H., Ewing B., et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011, 306:1359-1369. http://dx.doi.org/10.1001/jama.2011.1360.
152. Stein D.J. Neurobiology of the obsessive-compulsive spectrum disorders. Biol Psychiatry 2000, 47:296-304.
153. Zohar J., Insel T.R. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 1987, 22:667-687.
154. Zohar J., Zohar-Kadouch R.C., Kindler S. Current concepts in the pharmacological treatment of obsessive-compulsive disorder. Drugs 1992, 43:210-218.
155. Baumgarten H.G., Grozdanovic Z. Role of serotonin in obsessive-compulsive disorder. Br J Psychiatry Suppl 1998, 13-20.
156. Ozaki N., Goldman D., Kaye W.H., Plotnicov K., Greenberg B.D., Lappalainen J., et al. Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol Psychiatry 2003, 8:933-936. http://dx.doi.org/10.1038/sj.mp.4001365.
157. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999, 25:233-255.
158. Kern R.S., Green M.F., Marshall B.D., Wirshing W.C., Wirshing D., McGurk S.R., et al. Risperidone versus haloperidol on secondary memory: can newer medications aid learning?. Schizophr Bull 1999, 25:223-232.
159. Piontkewitz Y., Arad M., Weiner I. Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. Schizophr Bull 2011, 37:1257-1269. http://dx.doi.org/10./schbul/sbq040.1093.
160. Lerond J., Lothe A., Ryvlin P., Bouvard S., d'Amato T., Ciumas C., et al. Effects of aripiprazole, risperidone, and olanzapine on 5-ht1a receptors in patients with schizophrenia. J Clin Psychopharmacol 2013, 33:84-89. http://dx.doi.org/10.1097/JCP.0b013e397a6.1827.
161. Selvaraj S., Turkheimer F., Rosso L., Faulkner P., Mouchlianitis E., Roiser J.P., et al. Measuring endogenous changes in serotonergic neurotransmission in humans: a [11c]Cumi-101 pet challenge study. Mol Psychiatry 2012, 17:1254-1260. http://dx.doi.org/10.1038/mp.78.2012.
162. Cartmell J., Perry K.W., Salhoff C.R., Monn J.A., Schoepp D.D. Acute increases in monoamine release in the rat prefrontal cortex by the Mglu2/3 agonist Ly379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade. Neuropharmacology 2001, 40:847-855.
163. Bengtsson H.J., Kullberg A., Millan M.J., Hjorth S. The role of 5-Ht1a autoreceptors and alpha1-adrenoceptors in the modulation of 5-Ht release--Iii. clozapine and the novel putative antipsychotic S 16924. Neuropharmacology 1998, 37:349-356.
164. Huang M., Ichiwaka J., Li Z., Dai J., Meltzer H.Y. Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. Psychopharmacology (Berl) 2006, 185:274-281. http://dx.doi.org/10.1007/s00213-005-0206-1.
165. Hertel P., Nomikos G.G., Iurlo M., Svensson T.H. Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology (Berl) 1996, 124:74-86.
166. Hertel P., Lindblom N., Nomikos G.G., Svensson T.H. Modulation of central serotonergic neurotransmission by risperidone: underlying mechanism(s) and significance of action. Prog Neuropsychopharmacol Biol Psychiatry 1998, 22:815-834.
167. Hertel P., Nomikos G.G., Svensson T.H. The antipsychotic drug risperidone interacts with auto- and hetero-receptors regulating serotonin output in the rat frontal cortex. Neuropharmacology 1999, 38:1175-1184.
168. Kaminska K., Golembiowska K., Rogoz Z. Effect of risperidone on the fluoxetine-induced changes in extracellular dopamine, serotonin and noradrenaline in the rat frontal cortex. Pharmacol Rep 2013, 65:1144-1151.
169. Hertel P., Lindblom N., Nomikos G.G., Svensson T.H. Receptor-mediated regulation of serotonin output in the rat dorsal raphe nucleus: effects of risperidone. Psychopharmacology (Berl) 2001, 153:307-314.
170. Mason S.L., Reynolds G.P. Clozapine has sub-micromolar affinity for 5-Ht1a receptors in human brain tissue. Eur J Pharmacol 1992, 221:397-398.
171. Assie M.B., Sleight A.J., Koek W. Biphasic displacement of [3h]Ym-09151-2 binding in the rat brain by thioridazine, risperidone and clozapine, but not by other antipsychotics. Eur J Pharmacol 1993, 237:183-189.
172. Terai M., Hidaka K., Nakamura Y. Comparison of [3h]Ym-09151-2 with [3h]Spiperone and [3h]Raclopride for dopamine d-2 receptor binding to rat striatum. Eur J Pharmacol 1989, 173:177-182.
173. Noda-Saita K., Matsumoto M., Hidaka K., Hatanaka K., Ohmori J., Okada M., et al. Dopamine D4-like binding sites labeled by [3h]nemonapride include substantial serotonin 5-Ht2a receptors in primate cerebral cortex. Biochem Biophys Res Commun 1999, 255:367-370.